Horizon Pharma to acquire Vidara for about $660M
DEERFIELD, Ill. -- Horizon Pharma Inc. plans to buy the privately held Vidara Therapeutics International Ltd. in a cash-and-stock deal that will add the immune system disorder drug Actimmune to the specialty drugmaker's product portfolio.
Shares of Horizon soared in premarket trading Wednesday after the Deerfield, Ill., company said it will pay about $660 million in a deal that creates an Ireland-based company named Horizon Pharma PLC.
Vidara shareholders will receive $200 million in cash and retain about a 26 percent stake in Horizon Pharma PLC.
Horizon Chairman and CEO Timothy P. Walbert... read more